Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions

Table 1

Characteristics of the studies comparing International Prostatic Symptom score (IPSS) and prostate volume in patients with and without metabolic syndrome (MetS) according to different criteria. NCEP-ATPIII: National Cholesterol Education Program-Third Adult Treatment Panel; IDF: International Diabetes Federation; AHA/NHLBI: American Heart Association/National Heart, Lung, and Blood Institute.

Overall population			Men with MetS			Men without MetS
Study	MetS criteria	Age (years)	Number of pts	IPSS total score	Prostate volume (cc)	Number of pts	IPSS total score	Prostate volume (cc)
Ozden et al., 2007 [67]	NCEP ATP III	60	38	22	37.4	40	20	32
Park et al., 2008 [68]	NCEP ATP III	74 ± 8.1	102	11.1	41.7	246	12.3	40.4
Yim et al., 2011 [69]	NCEP ATP III	41.4 ± 5.2	140	—	18.4	708	—	17.8
Jeong et al., 2011 [70]	NCEP ATP III	46.4 ± 8.4	354	6.8	20.6	1003	6.5	19.7
Byun et al., 2011 [71]	NCEP ATP III	55.6 ± 9.72	209	6.85	31.4	499	7.89	29.8
Yang et al., 2012 [72]	NCEP ATP III	53.8 ± 6.9	142	—	30.1	278	—	25.2
Gacci et al., 2013 [4]	AHA/NHLBI; IDF	68.2 ± 7.4	86	22.5	63	185	20.9	58
Park et al., 2013 [73]	NCEP ATP III	50–59	355	10	34	869	10	28